Imunon (IMNN) investor relations material

Executive summary

• IMNN-001 demonstrated a 14.7-month median overall survival benefit in Phase 2 OVATION 2 for advanced ovarian cancer, with even greater benefit (24.2 months) when combined with PARP inhibitors.

• Enrollment in the pivotal Phase 3 OVATION 3 trial is progressing ahead of plan, with 80 patients targeted by Q1 2027 and full enrollment of 500 by Q1 2029.

• FDA has reviewed and aligned with the Phase 3 protocol, confirming the path to BLA filing and full approval based on overall survival endpoint.

• Strategic reorganization completed in Q1 2026 to optimize resources, reduce operating expenses, and support OVATION 3 trial execution.

• IMNN-101 COVID-19 booster vaccine completed Phase 1 with positive safety and immunogenicity data, but further development is paused pending partnerships.

Financial highlights

• Net loss for Q1 2026 was $4.3 million ($0.84 per share), compared to $4.1 million ($3.15 per share) in Q1 2025.

• Research and development expenses increased to $2.3 million from $2.2 million year-over-year, reflecting OVATION 3 trial initiation and OVATION 2 closure.

• General administrative expenses remained flat at $2.0–$2.2 million year-over-year.

• Net cash used in operating activities was $4.0 million in Q1 2026, up from $2.8 million in Q1 2025, mainly due to trial-related costs.

• Cash and cash equivalents stood at $4.8 million as of March 31, 2026, down from $8.8 million at year-end 2025.

Outlook and guidance

• OVATION 3 enrollment is on track, targeting 80 patients by Q1 2027 and full enrollment by Q1 2029.

• Two interim analyses are planned, with potential for early stopping for efficacy 1–2 years after full enrollment.

• Management has substantial doubt about the ability to continue as a going concern without additional capital.

• R&D Day scheduled for Q3 2026 to present final OVATION 2 efficacy and new translational data.

• Plans include raising funds through equity offerings, partnerships, and cost reductions.